Advancing Cancer Research with Plasma-Seq

Goal: Create a social media campaign on a new product and blog post.

Twitter: Plasma “Seq” and you shall find! Learn how researchers are using Takara’s ThruPlex Plasma-seq kits to identify minimally invasive, low-cost biomarkers from circulating tumor DNA. Read our new blog post here: [insert link]

LinkedIn: Innovative new approaches to detect cancer! Researchers are using Takara’s ThruPlex plasma-seq technology to profile circulating tumor DNA – genetic material released from dying cancer cells often found in plasma and cerebrospinal fluid. These minimally invasive, cost-effective biomarkers could aid in early cancer detection. Read more about the groundbreaking discoveries on our blog: [insert link]

Email:

Subject: Breakthroughs in cancer biomarker discovery: Easier, better, faster, cheaper

Body:

There is an urgent need to develop better screening tools for cancer. Current testing methods for many cancers are expensive, time-consuming, invasive, and low-throughput, thus hindering large-scale, early screening initiatives. 

Researchers have discovered a promising solution in circulating tumor DNA (ctDNA)  – genetic material released from dying cancer cells, commonly found in plasma or cerebrospinal fluid. ctDNA could serve as invaluable biomarkers for cancer. By using Takara’s ThruPlex plasma-seq technology, researchers have demonstrated the feasibility of using fluid biopsies and ctDNA to detect prostate and brain cancer, paving the way to potential breakthroughs in cancer screening.  

Learn more about these groundbreaking discoveries and our plasma-seq technology here: [insert link]